Allarity Therapeutics (NASDAQ: ALLR) shows new Phase 2 ovarian cancer data at AACR

Rhea-AI Filing Summary

Allarity Therapeutics, Inc. reported that Dr. Jeremy Graff, its President and Chief Development Officer, presented new and updated clinical data from the company’s ongoing Phase 2 trial in advanced ovarian cancer. The presentation took place at the American Association for Cancer Research 7th Biennial Special Conference on Ovarian Cancer, held September 19–21, 2025, at the Grand Hyatt Denver in Denver, Colorado.

The company also noted that a press release dated September 22, 2025, containing further details on the Phase 2 trial update has been issued and is included as an exhibit.

false 0001860657 0001860657 2025-09-22 2025-09-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 22, 2025

ALLARITY THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41160		87-2147982
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

123 E Tarpon Ave,

Tarpon Springs, FL 34689

(Address of principal executive offices)

(401) 426-4664

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ALLR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Matters.

On September 22, 2025, Allarity Therapeutics, Inc. (the “Company”) announced that announced that Dr. Jeremy Graff, the Company’s President and Chief Development Officer, presented new and updated clinical data from the ongoing Phase 2 clinical trial in advanced ovarian cancer patients at the American Association for Cancer Research (AACR) 7^th Biennial Special Conference on Ovarian Cancer, held September 19–21, 2025, at the Grand Hyatt Denver in Denver, Colorado. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release, dated September 22, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Allarity Therapeutics, Inc.
Date: September 24, 2025	By:	/s/ Thomas H. Jensen
		Thomas H. Jensen
		Chief Executive Officer

2

FAQ

What did Allarity Therapeutics (ALLR) disclose in this 8-K?

Allarity Therapeutics reported that Dr. Jeremy Graff, its President and Chief Development Officer, presented new and updated clinical data from an ongoing Phase 2 trial in advanced ovarian cancer at a major AACR ovarian cancer conference.

Which Allarity Therapeutics clinical trial was discussed in the AACR presentation?

The presentation covered new and updated clinical data from Allarity Therapeutics’ ongoing Phase 2 clinical trial in advanced ovarian cancer patients.

Where and when did Allarity Therapeutics present the new ovarian cancer data?

The data were presented at the AACR 7th Biennial Special Conference on Ovarian Cancer, held September 19–21, 2025, at the Grand Hyatt Denver in Denver, Colorado.

Who presented Allarity Therapeutics’ Phase 2 ovarian cancer data?

Dr. Jeremy Graff, Allarity Therapeutics’ President and Chief Development Officer, delivered the presentation on the Phase 2 advanced ovarian cancer trial.

Is there a press release with more details on Allarity Therapeutics’ trial update?

Yes. Allarity attached a press release dated September 22, 2025 as Exhibit 99.1, which is incorporated by reference and provides additional information on the Phase 2 ovarian cancer trial update.

Does the 8-K include any financial statements related to Allarity Therapeutics’ disclosure?

The 8-K lists exhibits, including the press release and a cover page interactive data file. It does not identify separate financial statements in connection with this other matters disclosure.